Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | LNPEP | Q9UIQ6 | 4/20 | 0.41 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | EPOR | P19235 | 1/20 | 0.37 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29641523 | 0.82 | SLC7A5 (0.52) | SLC7A5ITGB3ITGA2BLNPEPERAP2 | |
| SCHEMBL29909939 | 0.82 | SLC7A5 (0.52) | SLC7A5ITGB3ITGA2BLNPEPERAP2 | |
| SCHEMBL30759423 | 0.79 | GRIA1 (0.42) | LNPEPGRIA1 | |
| SCHEMBL30759400 | 0.79 | SLC7A5 (0.40) | SLC7A5LNPEPERAP2ERAP1 | |
| SCHEMBL30759435 | 0.77 | ERAP2 (0.53) | LNPEPERAP2ERAP1 | |
| SCHEMBL30759453 | 0.76 | SLC7A5 (0.42) | SLC7A5LNPEPERAP2 | |
| Tyrosine SCHEMBL27765246 | 0.76 | SLC7A5 (0.75) | SLC7A5ITGB3ITGA2BLNPEPERAP2 | |
| Acetic Acid SCHEMBL4291054 | 0.74 | SLC7A5 (0.49) | SLC7A5ITGB3ITGA2BLNPEPERAP2 | |
| SCHEMBL6275119 | 0.74 | SLC7A5 (0.51) | SLC7A5ITGB3ITGA2BLNPEPERAP2 | |
| Tyrosine SCHEMBL27709284 | 0.73 | SLC7A5 (0.71) | SLC7A5ITGB3ITGA2BLNPEPERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | SLC7A5 308/4885ITGB3 1796/4885ITGA2B 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.